#text { margin-left:0;} .sub_menu { display:none; }
Noticias
− Precisely sized, bioresorbable gelatin beads intended for embolization of
hypervascular tumors
− Designed for use by interventional radiologists who currently use
microspheres, PVA particles, and gelatin foam slurries
− Offers physicians a new treatment option when a permanent embolic agent is
not desired
MINNEAPOLIS, Minnesota -- Vascular Solutions, Inc. (Nasdaq: VASC) today
announced the U.S. market launch of its Gel-Bead embolization spheres for the treatment of
hypervascular tumors.
Gel-Bead embolization spheres are precisely sized, bioresorbable beads of gelatin that
are absorbed by the body over time, providing physicians with a treatment option for
hypervascular tumors in cases when a permanent embolic agent is not desired. Gel-Bead,
which received 510(k) clearance from the U.S. Food and Drug Administration in April, will be
sold to interventional radiologists who currently embolize hypervascular tumors with
microspheres, PVA particles, and gelatin foam slurries.
“We are very pleased to announce the launch of Gel-Bead, our latest offering to
leverage our biologics expertise in the field of embolization,” said Howard Root, Chief Executive
Officer of Vascular Solutions. “Our first vascular embolization product, Gel-Block, consists of a
pledget of gelatin foam that is radially compressed for superior delivery and was launched in
July 2012. Now, with the launch of Gel-Bead, we offer the additional configuration of uniform
spheres designed for smooth embolic delivery and predictable distribution, all at a very
economical price. Over time, we plan to continue to add to our embolization products with future
versions designed to meet specific therapeutic needs.”
Gel-Bead is supplied in 20ml syringes, each containing 1ml of gelatin spheres
suspended in 5ml of saline. Gel-Bead is available in four sizes of sphere diameter (100-300
microns, 300-500 microns, 500-700 microns, and 700-1,000 microns), each identified by a
different colored syringe plunger.